English | Spanish
ecancer
Supporting oncology professionals through education
Login Register

The content on this site is intended for healthcare professionals only

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

News

  • Latest news
  • Sign up for news alerts
  • Submit your news

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Journal information

  • Journal home
  • Charges
  • Editorial board
  • Founding editors
  • Editor-in-chief
  • Contact us

Author information

  • Submit article
  • Author guidelines
  • Editorial policies
  • Copyright information
  • Why publish with us

Reviewer information

  • Reviewer guidelines

Memberships

Open Access Scholarly Publishers Association Crossref Healthcare Information For All Commitee On Publication Ethics

Videos

  • Recent videos
  • Sign up

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Conferences

  • Latest conferences
  • Sign up for latest coverage
  • Submit your event

About ecancer

  • About ecancer
  • Our founders
  • Funding statement
  • Contact us
  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology
+ -
Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [3062]
News [6216]
Articles [124]
Editorials [18]
Conferences [183]
elearning [32]
IORT at Fortis Hospital Bangalore in India
Dr Sandeep Nayak - Fortis Hospital, Bangalore, India
IORT at Fortis Hospital Bangalore in India ( Dr Sandeep Nayak - Fortis Hospital, Bangalore, India )
3 Mar 2023
Improving access to palliative care by enhancing primary care services in an...
Dr Malar Velli Segarmurthy - Ministry of Health Malaysia, Putrajaya, Malaysia
Improving access to palliative care by enhancing primary care services in an upper middle-income country ( Dr Malar Velli Segarmurthy - Ministry of Health Malaysia, Putrajaya, Malaysia )
28 Feb 2023
Bladder sparing: Risk-enabled therapy after initiating neoadjuvant chemo allows...
Dr Daniel Geynisman - Fox Chase Cancer Center, Pennsylvania, USA
Bladder sparing: Risk-enabled therapy after initiating neoadjuvant chemo allows active surveillance of some MIBC ( Dr Daniel Geynisman - Fox Chase Cancer Center, Pennsylvania, USA )
24 Feb 2023
Pembrolizumab shows notable antitumour activity for patients with high-risk...
Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy
Pembrolizumab shows notable antitumour activity for patients with high-risk non–muscle-invasive bladder cancer ( Prof Andrea Necchi -  The Vita-Salute San Raffaele University, Milan, Italy )
23 Feb 2023
Latest in PARP inhibitors and combination therapies for prostate cancer
Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni...
Latest in PARP inhibitors and combination therapies for prostate cancer ( Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni Efstathiou )
19 Feb 2023
3 year follow-up of the CheckMate 9ER trial: NIVO + cabozantinib vs sunitinib...
Dr Mauricio Burotto - Bradford Hill, Recoleta, Chile
3 year follow-up of the CheckMate 9ER trial: NIVO + cabozantinib vs sunitinib for first-line treatment of aRCC ( Dr Mauricio Burotto - Bradford Hill, Recoleta, Chile )
19 Feb 2023
Plasma miR371 detects MRD and early relapse of germ cell tumours
Dr Lucia Nappi - University of British Columbia, Vancouver, Canada
Plasma miR371 detects MRD and early relapse of germ cell tumours ( Dr Lucia Nappi - University of British Columbia, Vancouver, Canada )
19 Feb 2023
Comparative cost-effectiveness of alternative imaging and surveillance...
Prof Robert Huddart - Royal Marsden NHS Foundation Trust, London, UK
Comparative cost-effectiveness of alternative imaging and surveillance schedules for testicular seminoma ( Prof Robert Huddart - Royal Marsden NHS Foundation Trust, London, UK )
19 Feb 2023
Adaptive image-guided radiotherapy in muscle-invasive bladder cancer shows low...
Prof Robert A Huddart - Royal Marsden NHS Foundation Trust, London, UK
Adaptive image-guided radiotherapy in muscle-invasive bladder cancer shows low toxicity and good outcomes ( Prof Robert A Huddart - Royal Marsden NHS Foundation Trust, London, UK )
18 Feb 2023
ASCO GU 2023: Latest updates in mRCC
Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor...
ASCO GU 2023: Latest updates in mRCC ( Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor Grünwald and Prof Toni Choueiri )
18 Feb 2023
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in...
Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC ( Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France )
18 Feb 2023
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC
Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )
18 Feb 2023
<1...4748495051...256>

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Desktop Site
  • Privacy Policy
© 2025 ecancer, all rights reserved
UK registered charity number: 1176307
Back to Top